JP2014530249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530249A5 JP2014530249A5 JP2014536344A JP2014536344A JP2014530249A5 JP 2014530249 A5 JP2014530249 A5 JP 2014530249A5 JP 2014536344 A JP2014536344 A JP 2014536344A JP 2014536344 A JP2014536344 A JP 2014536344A JP 2014530249 A5 JP2014530249 A5 JP 2014530249A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- use according
- ibs
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 24
- 229940002612 prodrug Drugs 0.000 claims 18
- 239000000651 prodrug Substances 0.000 claims 18
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 17
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims 13
- 229960002131 palonosetron Drugs 0.000 claims 13
- 239000012458 free base Substances 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- WAXQNWCZJDTGBU-UHFFFAOYSA-N netupitant Chemical compound C=1N=C(N2CCN(C)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WAXQNWCZJDTGBU-UHFFFAOYSA-N 0.000 claims 9
- 229960005163 netupitant Drugs 0.000 claims 9
- 238000011287 therapeutic dose Methods 0.000 claims 9
- 208000004998 Abdominal Pain Diseases 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 6
- 208000004296 neuralgia Diseases 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- 206010010774 Constipation Diseases 0.000 claims 4
- 206010012735 Diarrhoea Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000006186 oral dosage form Substances 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 2
- 206010000059 abdominal discomfort Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 230000010006 flight Effects 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000034347 Faecal incontinence Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003179 convulsant agent Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002550 fecal effect Effects 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000033001 locomotion Effects 0.000 claims 1
- 239000000014 opioid analgesic Substances 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 239000000902 placebo Substances 0.000 claims 1
- 229940068196 placebo Drugs 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 230000003238 somatosensory effect Effects 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 239000011885 synergistic combination Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548514P | 2011-10-18 | 2011-10-18 | |
| US61/548,514 | 2011-10-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530249A JP2014530249A (ja) | 2014-11-17 |
| JP2014530249A5 true JP2014530249A5 (enExample) | 2015-11-19 |
Family
ID=47178220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536344A Pending JP2014530249A (ja) | 2011-10-18 | 2012-10-10 | ネツピタントおよびパロノセトロンの治療学的組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9358228B2 (enExample) |
| EP (2) | EP2744497B1 (enExample) |
| JP (1) | JP2014530249A (enExample) |
| CN (3) | CN103889423B (enExample) |
| DK (1) | DK2744497T3 (enExample) |
| ES (1) | ES2579616T3 (enExample) |
| HK (1) | HK1198121A1 (enExample) |
| HU (1) | HUE030811T2 (enExample) |
| PL (1) | PL2744497T3 (enExample) |
| PT (1) | PT2744497T (enExample) |
| WO (1) | WO2013057554A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3435980T (pt) * | 2016-06-06 | 2020-02-21 | Helsinn Healthcare Sa | Formulações injetáveis fisiologicamente equilibradas de fosnetupitant |
| CN108721214B (zh) * | 2017-04-14 | 2020-06-16 | 和龙 | 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途 |
| TW202428273A (zh) | 2023-01-03 | 2024-07-16 | 瑞士商赫爾辛保健公司 | 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ236225A (en) | 1989-11-28 | 1992-09-25 | Syntex Inc | Azabicyclic-substituted isoquinoline derivatives, intermediates and pharmaceutical compositions |
| US5510486A (en) | 1994-07-26 | 1996-04-23 | Syntex (U.S.A.) Inc. | Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one |
| GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
| DE60042446D1 (de) * | 1999-02-18 | 2009-08-06 | Novasearch Ag | Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen |
| DK1394150T3 (da) | 1999-02-24 | 2011-03-21 | Hoffmann La Roche | 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister |
| CN1178917C (zh) | 2000-07-14 | 2004-12-08 | 弗·哈夫曼-拉罗切有限公司 | 作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物 |
| AU2002216085B8 (en) | 2000-12-14 | 2006-03-02 | F. Hoffmann-La Roche Ag | Self Emulsifying Lipid Matrix (SELM) |
| BRPI0406749A (pt) * | 2003-01-13 | 2005-12-20 | Dynogen Pharmaceuticals Inc | Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica |
| JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formulations of palonosetron |
| JO2676B1 (en) * | 2004-04-06 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines |
| MY142804A (en) | 2004-07-01 | 2011-01-14 | Opko Health Inc | Nk1 antagonists |
| EP2021005A4 (en) * | 2006-05-03 | 2009-11-25 | Cnsbio Pty Ltd | METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN |
| CA2666512C (en) | 2006-10-24 | 2014-05-27 | Helsinn Healthcare S.A. | Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability |
| US20100316678A1 (en) | 2007-06-28 | 2010-12-16 | Cnsbio Pty Ltd. | Combination methods and compositions for treatment of neuropathic pain |
| CN106512010A (zh) * | 2009-11-18 | 2017-03-22 | 赫尔辛医疗股份公司 | 用于治疗中枢介导的恶心及呕吐的组合物及方法 |
-
2012
- 2012-10-10 EP EP12784677.2A patent/EP2744497B1/en active Active
- 2012-10-10 PT PT127846772T patent/PT2744497T/pt unknown
- 2012-10-10 DK DK12784677.2T patent/DK2744497T3/en active
- 2012-10-10 CN CN201280051509.8A patent/CN103889423B/zh active Active
- 2012-10-10 CN CN201610834008.7A patent/CN106974912A/zh active Pending
- 2012-10-10 ES ES12784677.2T patent/ES2579616T3/es active Active
- 2012-10-10 US US14/351,113 patent/US9358228B2/en active Active
- 2012-10-10 CN CN201510670710.XA patent/CN105412110B/zh active Active
- 2012-10-10 PL PL12784677.2T patent/PL2744497T3/pl unknown
- 2012-10-10 JP JP2014536344A patent/JP2014530249A/ja active Pending
- 2012-10-10 WO PCT/IB2012/002013 patent/WO2013057554A2/en not_active Ceased
- 2012-10-10 EP EP14165604.1A patent/EP2759298B1/en active Active
- 2012-10-10 HU HUE12784677A patent/HUE030811T2/hu unknown
-
2014
- 2014-08-14 HK HK14110976.1A patent/HK1198121A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009541479A (ja) | 神経因性疼痛の治療用カンナビノイド | |
| CN104968368A (zh) | 固溶体组合物及其在剧痛中的用途 | |
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| JP2017510607A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| JP2017132791A (ja) | 組み合わせ組成物 | |
| AU2022202218A1 (en) | Combination Therapy Using Acamprosate And D-Cycloserine | |
| CA2735834C (en) | Composition comprising ibuprofen and paracetamol to treat pain caused by osteoarthritis and rheumatoid arthritis | |
| JP2016505050A5 (enExample) | ||
| CN105209044A (zh) | 用于疼痛病症的新的治疗性米氮平组合物 | |
| EP2759298B1 (en) | Therapeutic combinations of netupitant and palonosetron | |
| KR102927058B1 (ko) | 진통 가려움 완화 약학 조성물 및 그 응용 방법 | |
| JP2020527156A5 (enExample) | ||
| CN115835862A (zh) | 治疗阿尔茨海默病的组合及其应用 | |
| CN104117065B (zh) | 一种基于青藤碱的用于镇痛的药物组合产品 | |
| JP2024521430A5 (enExample) | ||
| RU2023116805A (ru) | 5'-o-фенилацетилуридин и терапевтическое применение | |
| CN117243948A (zh) | 包含瑞香素的组合物在制备风湿性关节炎药物中的应用 | |
| JPWO2009025091A1 (ja) | 線維筋痛症治療用医薬組成物 | |
| Peterson | Postherpetic neuralgia in the elderly: Debilitating and difficult to manage | |
| KR20200088861A (ko) | 우울증의 예방 또는 치료용 벤조익산 또는 이의 염 및 유도체 | |
| Barthunia et al. | Pregabalin and its Efficacy in Trigeminal Neuralgia–A Review | |
| CN103301124A (zh) | 一种治疗癫痫的药物组合物 | |
| WO2011000563A4 (en) | Eltoprazine for the treatment of weight disorders | |
| TW201325583A (zh) | 治療系統疾病藥品 |